Clinical trial NCT06933784: Evaluation of Wnt5a and LRP5 Levels in Serum and Saliva Samples and the Relationship Between Clinical Periodontal Parameters
Official title: Expression of Wnt5a and WNT Coreceptor (LRP5) Levels in Stage III Periodontitis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontal Disease
Periodontitis (Stage 3)
Periodontitis Stage III
Keywords: Wnt5a
LRP5
periodontitis
Lead sponsor: Ankara University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2025-04-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consisted of patients with stage III periodontitis and periodontally healthy patients admitted to Ankara University Faculty of Dentistry Clinic.

Brief summary: Objectives: Wnt5a is a secreted Wnt ligand that plays an important role in cellular homeostasis. Wnt interaction with coreceptor low-density lipoprotein receptor-related protein 5 (LRP5) induces the proliferation of osteoblasts and prolongs their functional life. The aim of this study is evaluating the levels of Wnt5a and LRP5 in serum and saliva samples and relationship between clinical periodontal parameters.

Method: Saliva and serum samples were collected from 20 systemically healthy patients with stage III periodontitis and 20 periodontally healthy controls. Wnt5a and LRP5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL) were recorded.


Eligibility criteria: Inclusion Criteria:

* \>18 years old,
* At least 16 permanent teeth except 3rd molars,
* Individuals who do not use orthodontic appliances,
* Individuals who are not pregnant or lactating,
* Individuals without any systemic disease that may affect periodontal health,
* Systemically healthy individuals,
* Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
* Individuals who have not received periodontal treatment in the last 1 year

Exclusion Criteria:

* Pregnant/lactating individuals,
* Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
* Individuals who have undergone periodontal treatment in the last 1 year,
* Individuals with psychiatric illness,
* Individuals with any oral infection,
* Individuals with \<16 teeth, excluding molars,
* Individuals with alcohol dependence,
* Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
* Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)

Primary outcomes:
measure: Wnt5a
timeFrame: 1 month
measure: LRP5
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara University, Faculty of Dentistry
state: Yenimahalle
Study officials:
References:
citation: Guney Z, Kurgan S, Onder C, Tayman MA, Gunhan O, Kantarci A, Serdar MA, Gunhan M. Wnt signaling in periodontitis. Clin Oral Investig. 2023 Nov;27(11):6801-6812. doi: 10.1007/s00784-023-05294-7. Epub 2023 Oct 10.
citation: Zhao Y, Zhang C, Huang Y, Yu Y, Li R, Li M, Liu N, Liu P, Qiao J. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-kappaB signaling in the granulosa cells of PCOS patients. J Clin Endocrinol Metab. 2015 Jan;100(1):201-11. doi: 10.1210/jc.2014-2419.
citation: Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009 Feb;24(2):171-8. doi: 10.1359/jbmr.081235.